---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-129610"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2022-12-22T23:59:59+00:00"
generated_at: "2026-06-21T00:06:07.692519+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics issues $31.82M convertible note to Streeterville; EMA accepts MAA for wet AMD

## Summary
- Net proceeds ~$30M from $31.82M face convertible note at 9.5%, maturing Jan 1, 2024; repays $11.9M existing note.
- Note convertible at $2.00/share; subject to 4.99% beneficial ownership cap (9.99% if market cap <$25M).
- Company must raise $25M new equity to close; shareholder approval required for issuances above 45.2M share cap.
- EMA validated MAA for ONS-5010 (bevacizumab-vikg) for wet AMD; EU decision expected early 2024.
- U.S. FDA BLA accepted with PDUFA Aug 29, 2023; potential 8-year EU exclusivity, extendable to 10.

## SEC filing metadata
- accession: 0001104659-22-129610
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2022-12-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465922129610/0001104659-22-129610-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465922129610/tm2233327d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-129610
- JSON: https://secwatch.observer/filing/0001104659-22-129610.json
- Plain text: https://secwatch.observer/filing/0001104659-22-129610.txt

## Key facts
- Material Agreements
  Outlook Therapeutics, Inc. entered into Securities Purchase Agreement with Streeterville Capital, LLC valued at $31,820,000 unsecured convertible promissory note, reflecting an original issue discount of $1,800,0 (effective 2022-12-22).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: Streeterville Capital, LLC
  - Value: $31,820,000 unsecured convertible promissory note, reflecting an original issue discount of $1,800,0
  - Effective: 2022-12-22
  source text: On December 22 2022, Outlook Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (“SPA”) with Streeterville Capital, LLC, a Utah limited liability company (the “Lender”), and, pursuant to the SPA, issued to the Lender an unsecured convertible promissory note with a face amount of $31,820,000 (the “Note”), reflecting an original issue discount of $1,800,000, for gross proceeds of approximately $30 million after deducting the Lender’s transaction costs covered by the Company in connection with the issuance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465922129610/0001104659-22-129610-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.